OBJECTIVE: This study aimed to evaluate the histologic and cytologic effects of preoperative vaginal estrogen in women with atrophic vaginitis and pelvic organ prolapse. METHODS:Forty-two women with atrophic vaginitis and stage greater than or equal to 2 prolapse were enrolled in this assessor-blinded randomized controlled trial comparing daily vaginal estrogen cream use for 2 to 12 weeks preoperatively versus no intervention. Data were analyzed using t test and analysis of variance. RESULTS: Of these 42 women, 22 received treatment and 20 were controls. After a mean 7 (3) weeks of use, the vaginal maturity index increased 15.5% in the treatment group and declined 1.5% in the control group (P < 0.001). The vaginal epithelial thickness was 339 (96) μm in the treatment group compared to 302 (119) μm (P = 0.275) in the controls. CONCLUSIONS:Preoperative vaginal estrogen application for 2 to 12 weeks restores vaginal cytology to premenopausal levels, but does not increase vaginal epithelial thickness in women with prolapse.
RCT Entities:
OBJECTIVE: This study aimed to evaluate the histologic and cytologic effects of preoperative vaginal estrogen in women with atrophic vaginitis and pelvic organ prolapse. METHODS: Forty-two women with atrophic vaginitis and stage greater than or equal to 2 prolapse were enrolled in this assessor-blinded randomized controlled trial comparing daily vaginal estrogen cream use for 2 to 12 weeks preoperatively versus no intervention. Data were analyzed using t test and analysis of variance. RESULTS: Of these 42 women, 22 received treatment and 20 were controls. After a mean 7 (3) weeks of use, the vaginal maturity index increased 15.5% in the treatment group and declined 1.5% in the control group (P < 0.001). The vaginal epithelial thickness was 339 (96) μm in the treatment group compared to 302 (119) μm (P = 0.275) in the controls. CONCLUSIONS: Preoperative vaginal estrogen application for 2 to 12 weeks restores vaginal cytology to premenopausal levels, but does not increase vaginal epithelial thickness in women with prolapse.
Authors: David D Rahn; Renée M Ward; Tatiana V Sanses; Cassandra Carberry; Mamta M Mamik; Kate V Meriwether; Cedric K Olivera; Husam Abed; Ethan M Balk; Miles Murphy Journal: Int Urogynecol J Date: 2014-11-13 Impact factor: 2.894
Authors: David D Rahn; Meadow M Good; Shayzreen M Roshanravan; Haolin Shi; Joseph I Schaffer; Ravinder J Singh; R Ann Word Journal: J Clin Endocrinol Metab Date: 2014-06-20 Impact factor: 5.958
Authors: M-L Marschalek; K Bodner; O Kimberger; S Zehetmayer; R Morgenbesser; W Dietrich; C Obruca; H Husslein; W Umek; H Koelbl; B Bodner-Adler Journal: BJOG Date: 2021-09-21 Impact factor: 7.331
Authors: David D Rahn; Holly E Richter; Vivian W Sung; Wilma I Larsen; Linda S Hynan Journal: Female Pelvic Med Reconstr Surg Date: 2021-01-01 Impact factor: 1.913